全文获取类型
收费全文 | 5485篇 |
免费 | 344篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 137篇 |
妇产科学 | 115篇 |
基础医学 | 836篇 |
口腔科学 | 73篇 |
临床医学 | 438篇 |
内科学 | 1466篇 |
皮肤病学 | 105篇 |
神经病学 | 544篇 |
特种医学 | 153篇 |
外科学 | 499篇 |
综合类 | 18篇 |
一般理论 | 1篇 |
预防医学 | 219篇 |
眼科学 | 66篇 |
药学 | 326篇 |
中国医学 | 5篇 |
肿瘤学 | 844篇 |
出版年
2024年 | 12篇 |
2023年 | 66篇 |
2022年 | 143篇 |
2021年 | 229篇 |
2020年 | 152篇 |
2019年 | 188篇 |
2018年 | 198篇 |
2017年 | 121篇 |
2016年 | 151篇 |
2015年 | 195篇 |
2014年 | 206篇 |
2013年 | 254篇 |
2012年 | 417篇 |
2011年 | 410篇 |
2010年 | 224篇 |
2009年 | 217篇 |
2008年 | 327篇 |
2007年 | 260篇 |
2006年 | 275篇 |
2005年 | 217篇 |
2004年 | 204篇 |
2003年 | 206篇 |
2002年 | 181篇 |
2001年 | 92篇 |
2000年 | 96篇 |
1999年 | 108篇 |
1998年 | 52篇 |
1997年 | 38篇 |
1996年 | 27篇 |
1995年 | 23篇 |
1994年 | 14篇 |
1993年 | 22篇 |
1992年 | 55篇 |
1991年 | 45篇 |
1990年 | 49篇 |
1989年 | 48篇 |
1988年 | 38篇 |
1987年 | 40篇 |
1986年 | 41篇 |
1985年 | 27篇 |
1983年 | 16篇 |
1982年 | 10篇 |
1979年 | 15篇 |
1978年 | 19篇 |
1973年 | 13篇 |
1970年 | 10篇 |
1969年 | 11篇 |
1968年 | 10篇 |
1967年 | 10篇 |
1966年 | 15篇 |
排序方式: 共有5873条查询结果,搜索用时 15 毫秒
101.
102.
Stefano Sansone Maria Guarino Fabiana Castiglione Antonio Rispo Francesco Auriemma Ilaria Loperto Matilde Rea Nicola Caporaso Filomena Morisco 《World journal of gastroenterology : WJG》2014,20(13):3516-3524
In recent years,a number of case reports and clinical studies have highlighted the risk of hepatitis B and C virus reactivation in patients with inflammatory bowel disease who are treated with immunosuppressive drugs.The cases of viral hepatitis reactivation that have been reported are characterized by a wide range of clinical manifestations,from viremia without clinically relevant manifestations to fulminant life-threatening hepatitis.The development and dissemination of biological immunosuppressive drugs have led to a significant increase in the number of reports of interest to physicians in a variety of clinical settings.On this topic,there have been a number of published guidelines and reviews that have collected the available evidence,providing recommendations on prophylactic and therapeutic strategies and methods for monitoring patients at risk.However,it should be noted that,to date,very few clinical studies have been published,and most of the recommendations have been borrowed from otherclinical settings.The published studies are mostly retrospective and are based on very heterogeneous populations,using different therapeutic and prophylactic regimens and obtaining conflicting results.Thus,it seems clear that it is desirable to concentrate our efforts on prospective studies,not conducting further reviews of the literature in the continued absence of new evidence. 相似文献
103.
104.
Antonelli A Ferrari SM Frascerra S Ruffilli I Pupilli C Bernini G Sellari-Franceschini S Gelmini S Ferrannini E Fallahi P 《The Journal of endocrinology》2012,213(2):183-191
No data are present in the literature about the effect of cytokines on the prototype β chemokine (C-C motif) ligand 2 (CCL2) or of peroxisome proliferator-activated receptor α (PPARα (PPARA)) activation on CCL2 and CXCL10 chemokines secretion in fibroblasts or preadipocytes in Graves' ophthalmopathy (GO). We have tested the effect of interferon γ (IFNγ (IFNG)) and tumor necrosis factor α (TNFα) on CCL2, and for comparison on the prototype α chemokine (C-X-C motif) ligand 10 (CXCL10), and the possible modulatory role of PPARα activation on secretion of these chemokines in normal and GO fibroblasts or preadipocytes in primary cell cultures. This study shows that IFNγ alone, or in combination with TNFα, stimulates the secretion of CCL2 in primary orbital fibroblasts or preadipocytes from patients with GO at levels similar to those observed in controls. IFNγ and TNFα also stimulated CXCL10 chemokine secretion as expected. The presence of PPARα and PPARγ (PPARG) in primary fibroblasts or preadipocytes of patients with GO has been confirmed. PPARα activators were able to inhibit the secretion of CXCL10 and CCL2, while PPARγ activators were confirmed to be able to inhibit CXCL10 but had no effect on CCL2. PPARα activators were stronger inhibitors of chemokine secretions than PPARγ agonists. In conclusion, CCL2 and CXCL10 are modulated by IFNγ and TNFα in GO. PPARα activators inhibit the secretion of the main prototype α (CXCL10) and β (CCL2) chemokines in GO fibroblasts or preadipocytes, suggesting that PPARα may be involved in the modulation of the immune response in GO. 相似文献
105.
106.
Gianluca Bardini Ilaria Dicembrini Carlo Maria Rotella Stefano Giannini 《Metabolism: clinical and experimental》2012,61(12):1674-1677
ObjectiveThe objective was to evaluate the seasonal lipid variations in type 2 diabetic (DM2) outpatients.Materials/Methods302 (183 women and 119 men) DM2 subjects with or without statins therapy were screened. Body weight, HbA1c, total cholesterol (TC), high density lipoprotein (HDL-C), triglycerides (Trg) and low density lipoprotein cholesterol (LDL-C) were measured and patients’ data of diet and physical activity were recorded during fall/winter (F/W) and spring/summer (S/S) seasons.ResultsHbA1c levels showed seasonal variability without statistical significance. During the colder seasons we observed an increase (P<.05) of weight associated with higher calorie intake and reduced physical activity. We showed a peak of TC, LDL-C and Trg levels during F/W while HDL-C levels were reduced. Median TC levels in F/W with respect to S/S were 197 vs 185 mg/dL (P<.001) without statins therapy and 172 vs 161 mg/dL (P<.001) in patients under statins therapy. Median LDL-C levels, without or with statin therapy, were 122 vs 114 mg/dL (P<.001) and 97.5 vs 88.5 mg/dL (P<.001), respectively. This seasonal lipids changes from F/W to S/S, modulated the percent of patients at LDL-C target < 100 mg/dL, both without or under statins treatment: from 22% to 29.5% (P<.05) with odds ratio 0.73 (95% CI 0.62–0.87) and from 47% to 55% (P<.001) with odds ratio 0.68 (95% CI 0.58–0.76), respectively.ConclusionsDM2 patients showed a peak of TC and LDL-C during colder months associated with changes of diet and lifestyle habits. This seasonal lipid trend modified the percentage of patients at LDL-C therapeutical target. 相似文献
107.
108.
109.
P Villa S Soriano T Tsanova I Degano TF Higham F d'Errico L Backwell JJ Lucejko MP Colombini PB Beaumont 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(33):13208-13213
The transition from the Middle Stone Age (MSA) to the Later Stone Age (LSA) in South Africa was not associated with the appearance of anatomically modern humans and the extinction of Neandertals, as in the Middle to Upper Paleolithic transition in Western Europe. It has therefore attracted less attention, yet it provides insights into patterns of technological evolution not associated with a new hominin. Data from Border Cave (KwaZulu-Natal) show a strong pattern of technological change at approximately 44-42 ka cal BP, marked by adoption of techniques and materials that were present but scarcely used in the previous MSA, and some novelties. The agent of change was neither a revolution nor the advent of a new species of human. Although most evident in personal ornaments and symbolic markings, the change from one way of living to another was not restricted to aesthetics. Our analysis shows that: (i) at Border Cave two assemblages, dated to 45-49 and >49 ka, show a gradual abandonment of the technology and tool types of the post-Howiesons Poort period and can be considered transitional industries; (ii) the 44-42 ka cal BP assemblages are based on an expedient technology dominated by bipolar knapping, with microliths hafted with pitch from Podocarpus bark, worked suid tusks, ostrich eggshell beads, bone arrowheads, engraved bones, bored stones, and digging sticks; (iii) these assemblages mark the beginning of the LSA in South Africa; (iv) the LSA emerged by internal evolution; and (v) the process of change began sometime after 56 ka. 相似文献
110.